trial
as of 2026-07-01Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients
NCTId NCT01105481
at a glance
Phase 4 · Completed
Enrollment 273 (actual)
Sponsored by National Health Research Institutes, Taiwan
Primary completion 2008-03
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
273 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2006-05
Primary completion
2008-03
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Sponsors
National Health Research Institutes, TaiwanLead Sponsor
Investigators
1
Sheng-Chang Wang, M.D.,M.Sc.Principal Investigator
Sites
2 total
Taipei County, TaiwanTaoyuan, Taiwan
Facts & assertions
4 sourced
Enrollment
273
Phase
PHASE4
Primary Completion Date
2008-03
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
indication
investigator